A Randomized, Open-label Phase 3 Study of Amivantamab + mFOLFOX6 or FOLFIRI Versus Cetuximab + mFOLFOX6 or FOLFIRI as First-line Treatment in Participants with RAS/RAF Wild-Type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Janssen Research & Development, LLC
The purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapies. to participants with metastatic CRC that lack mutations in genes called KRAS/NRAS and BRAF. Cetuximab, FOLFIRI and mFOLFOX6 therapy is already used to treat participants with your type of cancer.
Enrollment Form
This study is currently enrolling.